Utplassering på patologen ga mersmak

Åtte elever fra Ullern videregående skole har denne uken vært på utplassering hos avdeling for patologi ved Oslo universitetssykehus. Morsomt har det vært, og Marie Wahlstrøm kan godt tenke seg å bli patolog.
Targovax's logo

Targovax ASA moves share listing to Oslo Børs

Targovax ASA's shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange. Targovax is a clinical stage company, developing immuno-oncology therapies to target treatment-resistant solid tumors.

Kick-Off: Call for Proposals for PERMIDES

The first call for proposals for the PERMIDES project is opening on March 15th. We urge all small and medium sized biopharma-companies working to take the step into the digital era: Apply for funding up to 60 000 Euros.

BerGenBio enters collaboration with MSD

Oslo Cancer Cluster member BerGenBio enters collaboration with MSD focused on clinical evaluation of BGB324 in combination with KEYTRUDA® (pembrolizumab) in advanced lung and breast cancer.

We are hiring an EU Advisor

We are currently looking for an EU advisor with skills and experience in writing EU funding proposals. This is a fixed term contract with duration to the end of 2018.
Targovax's logo

Targovax to present at upcoming conferences

Oslo, Norway, 6 March 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences: - 10th European Life Science CEO Forum - Redeye - Fight Cancer Seminar - 11th Annual BIO-Equity Spring 2017 Conference